Overview
| 别名 | Protein S100-A16; Aging-associated gene 13 protein; Protein S100-F; S100 calcium-binding protein A16 |
| 基因名 | S100A16 |
| UniProt ID | Q96FQ6 |
| 反应种属 | Human |
| 应用 | IHC-P |
| 宿主 | Mouse |
| 偶联物 | Unconjugated |
| 修饰 | Unmodified |
| 亚型 | IgG1 |
| 克隆号 | 5R1-M2-A3 |
| 克隆性 | Monoclonal Antibody |
| 分子量 | Calculated MW: 11 kDa |
| 纯化方式 | Affinity Purified |
| 产品形式 | Liquid |
| 推荐稀释比 | IHC-1:100-1:200 |
| 存储缓冲液 | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.09% sodium azide |
| 保存温度 | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| 背景信息 | S100 calcium binding protein A16 (S100A16) is a small acidic cytoplasmic protein of the S100 family characterized by EF-hand calcium-binding motifs. It functions as a homodimer in calcium-dependent signaling pathways, participating in cell proliferation, migration, and epithelial-mesenchymal transition (EMT). S100A16 often exerts its effects by regulating the ubiquitin-mediated degradation of target proteins, such as LATS1 and ZO-2. Clinically, S100A16 is consistently upregulated in various malignancies, including glioma and gastric cancer, where high expression correlates with poor prognosis. In glioma, it promotes invasion by enhancing CUL4A-mediated degradation of LATS1, thereby inhibiting Hippo signaling and increasing nuclear YAP activity. In gastric cancer, it drives metastasis and EMT by promoting the degradation of the tight junction protein ZO-2, facilitating tumor spread. |
检测原理